title: Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer.
abstract: Claudins are integral tight junction proteins that are responsible for maintaining the integrity of epithelial cell architecture and cell polarity. Claudin-3 and -4 are overexpressed in several cancers and have been shown to act as receptors for the Clostridium perfringens enterotoxin (CPE), a toxin that causes rapid cell lysis. CPE has demonstrated effectiveness in treating several different cancers in mouse models, provided that these cancers express claudin-3 or claudin-4. Here, we show that claudin-3/4 expression is not an absolute requirement for CPE action and, through overexpression and knockdown experiments, we identify claudin-6 as a novel functional receptor for CPE. Indeed, UCI-101, an ovarian cancer cell line highly sensitive to CPE, does not express claudin-3/4 and knockdown of claudin-6 in these cells decreases CPE sensitivity. Moreover, two different ovarian cell lines that are resistant to the effects of CPE can be made sensitive through claudin-6 overexpression. Binding assays show that CPE can indeed bind claudin-6 in cells and that this binding is associated with CPE cytotoxicity. Multicellular tumor spheroids experiments demonstrate that claudin-6 can also be a target of CPE in three-dimensional cultures. Our data establish claudin-6 as a novel receptor for CPE and introduces the possibility of a novel targeted therapeutic for ovarian and other cancers that express claudin-6.
authors.affiliation: Laboratory of Molecular Biology and Immunology, National Institute on Aging, NIH, Biomedical Research Center, Baltimore MD, USA.
authors.forename: M
authors.initials: M
authors.lastname: Lal-Nag
authors.forename: M
authors.initials: M
authors.lastname: Battis
authors.forename: A D
authors.initials: AD
authors.lastname: Santin
authors.forename: P J
authors.initials: PJ
authors.lastname: Morin
references.citation: Toxins (Basel). 2010 Jul;2(7):1595-611
references.pmid: 22069652
references.citation: Cancer Res. 2005 Nov 1;65(21):9603-6
references.pmid: 16266975
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3339-46
references.pmid: 17545541
references.citation: Am J Pathol. 2004 May;164(5):1627-33
references.pmid: 15111309
references.citation: PLoS One. 2011;6(7):e22119
references.pmid: 21789222
references.citation: Dev Dyn. 2001 Oct;222(2):292-300
references.pmid: 11668606
references.citation: FEBS Lett. 2000 Jul 7;476(3):258-61
references.pmid: 10913624
references.citation: Cancer Invest. 2011 Jan;29(1):1-11
references.pmid: 20874001
references.citation: Curr Med Chem. 2011;18(12):1861-5
references.pmid: 21466467
references.citation: J Gastrointest Cancer. 2010 Mar;41(1):52-9
references.pmid: 19960275
references.citation: J Biol Chem. 2008 Nov 7;283(45):30585-95
references.pmid: 18782762
references.citation: Expert Rev Mol Med. 2006 Aug 04;8(18):1-11
references.pmid: 16887048
references.citation: J Breast Cancer. 2011 Mar;14(1):20-7
references.pmid: 21847390
references.citation: Gastroenterology. 2001 Sep;121(3):678-84
references.pmid: 11522752
references.citation: Cancer Res. 2005 May 15;65(10):4334-42
references.pmid: 15899825
references.citation: Cancer. 2007 Apr 1;109(7):1312-22
references.pmid: 17326053
references.citation: Int J Mol Sci. 2011 Feb 22;12(2):1334-58
references.pmid: 21541062
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Dev Dyn. 2008 Feb;237(2):504-12
references.pmid: 18213590
references.citation: Prostate. 2012 Mar;72(4):351-60
references.pmid: 21656836
references.citation: Cancer Cell. 2012 Apr 17;21(4):455-8
references.pmid: 22516256
references.citation: J Biol Chem. 2009 Jul 10;284(28):18863-72
references.pmid: 19429681
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: J Biol Chem. 1997 Oct 17;272(42):26652-8
references.pmid: 9334247
references.citation: Cancer Res. 2000 Nov 15;60(22):6281-7
references.pmid: 11103784
references.citation: Int J Cancer. 2004 Oct 20;112(1):14-25
references.pmid: 15305371
references.citation: BMC Cancer. 2006 Jul 12;6:186
references.pmid: 16836752
references.citation: Cell Res. 2012 Jun;22(6):1082-5
references.pmid: 22565286
references.citation: Eur J Cancer Prev. 2010 May;19(3):186-94
references.pmid: 20215972
references.citation: Lancet. 2009 Oct 17;374(9698):1371-82
references.pmid: 19793610
references.citation: Gene Ther. 2012 May;19(5):494-503
references.pmid: 21975465
references.citation: Brain Pathol. 2010 Jan;20(1):140-50
references.pmid: 19220299
references.citation: Am J Clin Pathol. 2007 Jun;127(6):928-37
references.pmid: 17509990
references.citation: Gynecol Oncol. 2006 Nov;103(2):405-16
references.pmid: 16725184
references.citation: Am J Surg Pathol. 2012 Jan;36(1):73-80
references.pmid: 21989342
references.citation: Clin Cancer Res. 2003 Jul;9(7):2567-75
references.pmid: 12855632